

1 **Original Article:**

2

3 **Title of the Manuscription:**

4 **Evaluation of the antibody response and adverse reactions of the BNT162b2 vaccine of**
5 **participants with prior COVID-19 infection in Japan**

6

7 Names of the Authors:

8 Toshiya Mitsunaga^{1,2}, Yuhei Ohtaki², Yutaka Seki^{1,3,4}, Masakata Yoshioka⁴, Hiroshi Mori⁵, Midori
9 Suzuka⁶, Syunsuke Mashiko², Satoshi Takeda², Kunihiro Mashiko¹.

10

11 Institutional Affiliations of the Authors:

12 ¹ Department of Emergency Medicine, Association of EISEIKAI Medical and Healthcare
13 Corporation Minamitama Hospital, Tokyo, Japan

14 ² Department of Emergency Medicine, Jikei University School of Medicine, Tokyo, Japan

15 ³ Department of Cardiology, Association of EISEIKAI Medical and Healthcare Corporation
16 Minamitama Hospital, Tokyo, Japan

17 ⁴ Department of Internal Medicine, Association of EISEIKAI Medical and Healthcare Corporation
18 Minamitama Hospital, Tokyo, Japan

19 ⁵ Department of Medical Engineering, Association of EISEIKAI Medical and Healthcare
20 Corporation Minamitama Hospital, Tokyo, Japan

21 ⁶ Department of Pharmacy, Association of EISEIKAI Medical and Healthcare Corporation
22 Minamitama Hospital, Tokyo, Japan

23

24 Corresponding Author's Information:

25 Name: Toshiya Mitsunaga¹⁻³

26 Address: 3-10-1, Sanda-machi, Hachioji-city, Tokyo, 1930832, Japan

27 Telephone Number: 042-663-0111

28 Email Address: toshiya.m@jikei.ac.jp

29

30 Keywords: COVID-19, vaccine, antibody, adverse reaction, prior infection.

31

32

33

34

35

36

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 **ABSTRACT:**

38 **Introduction**

39 Vaccination programs are important to preventing COVID-19 infection. BNT162b2 is new type of
40 vaccine, and previous studies have shown that the antibody response was significantly elevated in
41 patients with prior COVID-19 infection after the first vaccination. However, no study has evaluated
42 the efficacy of the vaccination or the adverse reactions of people with prior COVID-19 infection in
43 Japan. The aim of this study is to evaluate the antibody titer and adverse reactions of BNT162b2
44 vaccine among participants with prior COVID-19 infection in Japan.

45 **Methods**

46 The data for this study was collected between April 15, 2021, and June 9, 2021. All of the hospital
47 staff who received the BNT162b2 vaccine were included in this study and were sorted into either the
48 prior infection group or the control group. We collected the data of adverse reactions through
49 self-reporting and calculated the anti-SARS-CoV-2 spike-specific antibody titer for all participants.

50 **Results**

51 The antibody titer of the prior-infection group in first antibody test was significantly higher than that
52 of the control group in the second antibody test. There was no significant difference in adverse
53 reactions between the prior infection group receiving its first vaccination and the control group
54 receiving its second vaccination.

55 **Conclusion**

56 Our study shows that the antibody response following the first vaccination in the prior COVID-19
57 infection group was found to be comparable to that of the second vaccination in the control group;
58 however, the evaluation of adverse reactions was inadequate and further, large-scale studies are
59 needed.

60

61

62

63

64

65

66

67

68

69

70

71 **Introduction**

72 At the end of 2019, a new pathogen named the severe acute respiratory syndrome coronavirus 2
73 (SARS-CoV-2) was identified. The coronavirus 2019 (COVID-19) has since spread rapidly all over
74 the world, and the number of COVID-19 cases has reached more than 180 million with four million
75 COVID-19 patients dead (mortality rate: 2.16%) [1]. In Japan, The Ministry of Health, Labor and
76 Welfare has reported that the number of COVID-19 cases in Japan was 798,159, with 14,740 deaths
77 by 30 June 2021 (mortality rate: 1.85%) [2]. Countries around the world are trying to reduce their
78 rates of COVID-19 infection, but this is difficult to control due to the virus's strong infectivity.
79 Treatment plans such as steroids, antivirals, ventilators, etc. have been put in place, but vaccination is
80 still a crucial strategy for preventing COVID-19 infection. BNT162b2 is a new type of vaccine
81 composed of a nucleoside-modified RNA vaccine that encodes a full-length SARS-CoV-2 spike
82 glycoprotein [3]. A study carried out by Polack et al. showed that the vaccine's efficacy for
83 preventing COVID-19 is about 95% [3], and we are administering two doses of the vaccine to boost
84 immunity. The study carried by Walsh et al. showed that spike-binding IgG titer increased
85 dramatically and reached a plateau after seven days of receiving the second vaccination, whereas the
86 titer was slightly elevated after seven days of receiving the first vaccination [4].
87 Previous studies carried out by Charlotte et al. and Ebinger et al. showed that the antibody-titer level
88 was significantly elevated in patients with a history of prior COVID-19 infection after receiving the
89 first vaccination [5, 6] but this level was merely maintained after these patients received the second
90 vaccination. Although there are several studies in this field, no study has evaluated the effects of the
91 first and second vaccinations on people who had previously experience a COVID-19 infection in
92 Japan. Furthermore, no study has evaluated the adverse reactions to the BNT162b2 vaccine for
93 people with prior COVID-19 infection. The aim of this study is to evaluate the antibody titer and
94 adverse reactions to the BNT162b2 vaccine among subjects with a history of COVID-19 infection in
95 Japan.

97 **Materials and Methods**

98 **Study Design and Setting**

99 This prospective study, which builds upon our previous study [7] by adding the data of a prior
100 COVID-19 infection group, was carried out between April 15, 2021, and June 9, 2021, at the
101 Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, an urban
102 hospital with 170 beds. The protocol for this research project was approved by the Ethics Committee
103 of the institution, it conforms to the provision of the Declaration of Helsinki (Committee of the

104 Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, Approval No.
105 2020-Ack-19) and written consent was obtained from all the participants.

106 All our hospital's staff who received the BNT162b2 vaccine as a part of a routine program were
107 included in this study. The exclusion criteria were as follows: 1) cases did not give informed consent,
108 2) cases that exhibited a new COVID-19 infection following vaccination, 3) cases that did not
109 provide a blood sample within the expected deadline (i.e., twenty days post-vaccination), and 4)
110 cases that did not submit a questionnaire about adverse reactions.

111 The participants with a history of prior COVID-19 infection or whose antibody titer was positive
112 before the administration of the BNT162b2 vaccine were included in this study as part of the prior
113 COVID-19 infection group, whereas the participants without a history of prior COVID-19 infection
114 or who presented with a negative antibody titer before vaccination were included as the control
115 group.

116 We obtained 5-ml blood samples from the intermediate cubital vein and calculated the
117 anti-SARS-CoV-2 spike-specific antibody titer for each participant (Elecsys[®] Anti-SARS-CoV-2 S
118 RUO, Roche Diagnostics K.K.) 1) before vaccination (baseline), 2) seven to twenty days after the
119 first dose of the vaccination (first antibody test), and 3) seven to twenty days after the second dose of
120 the vaccination (second antibody test).

121 We also calculated the blood cell count (WBC: White Blood Cells, Hb: Hemoglobin, Ht: Hematocrit,
122 and PLT: Platelets) and conducted biochemical examinations (AST: aspartate aminotransferase,
123 ALT: alanine aminotransferase, γ -GT: γ -glutamyl transpeptidase, Alb: albumin, TG: triglyceride,
124 HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, Cr:
125 Creatinine, BS: Blood Sugar, HbA1c: Hemoglobin A1c, CRP: c-reactive protein) before vaccination.

126 The information of age; gender; height; body weight; body mass index (BMI); past medical history
127 (1. Chronic lung disease (Chronic obstructive pulmonary disease: COPD), 2. Chronic lung disease
128 (non-COPD), 3. Cardiac disease, 4. Hypertension, 5. Diabetes, 6. Dyslipidemia, 7. Liver disease, 8.
129 Chronic kidney disease, 9. Autoimmune disease, 10. Cancer); medication (1. Antihypertensive drugs,
130 2. Antidiabetic drugs, 3. Antilipid drugs, 4. Antiplatelet and Anticoagulant drugs, 5.

131 Immunosuppressive drugs, 6. Immunoglobulin); smoking habits (current and previous history of
132 smoking); habits of drinking alcohol; and adverse reactions (1. pain/redness/swelling, 2. fever, 3.
133 fatigue, 4. headache, 5. chills, 6. diarrhea, 7. myalgia, 8. arthralgia, 9. others) were recorded via self
134 reporting. Cases with missing values were not excluded, and the acquired values were used for
135 analysis.

136

137 **Statistical Analyses**

138 A sample size of 475 participants was determined based upon 70% power, 0.05 significance level,
139 0.8 effect size, 37 allocation ration, and 20% attrition.
140 Continuous variables were described as medians and interquartile ranges (IQR) and were compared
141 using a Mann-Whitney *U*-test. Categorical variables were expressed as numbers and percentages and
142 were compared using Fisher's exact test. Analysis of variance (ANOVA) and Fisher's exact test
143 were used to test differences among the groups. Multivariate logistic regression analysis was
144 performed to ascertain the effects of factors such as the likelihood of local adverse reactions or
145 systemic adverse reactions. Odds ratios and corresponding 95% confidence intervals were calculated.
146 A *p*-value of less than 0.05 was considered to indicate statistical significance. Data were analyzed
147 with the Statistical Package for the Social Sciences, version 26.0 (SPSS, Chicago, IL, USA).

148

149 **Results**

150 Overall, 501 participants met the inclusion criteria. However, 96 participants were excluded because
151 they did not provide their consent to the study, one participant was excluded because of a new
152 COVID-19 infection after vaccination, and twenty-one participants were excluded because they did
153 not provide a blood sample within the deadline. Finally, 383 (76.4%) participants, who were divided
154 into a nine-person prior COVID-19 infection group and a 374-person control group, were analyzed
155 (Fig 1).

156 The data of the antibody titer of the second antibody test in the prior COVID-19 infection group was
157 missing for one case, and the data of adverse reactions was missing for two cases in the prior
158 COVID-19 infection group and for fifteen cases in control group.

159 The baseline characteristics for the prior COVID-19 infection group and control group are
160 demonstrated in Table 1. The median age (interquartile range) of the participants was younger in the
161 prior COVID-19 infection Group than in the Control Group (26 (16.0) vs 36 (16.0): $p = 0.12$), but
162 there were no other significant differences. The proportion of males was slightly smaller in the prior
163 COVID-19 infection group, but the difference was not significant ($p = 0.46$). Moreover, there was no
164 obesity and only a few participants with a previous medical history in the prior COVID-19 infection
165 group.

166 The comparison of anti-SARS-CoV-2 spike-specific antibody response between the prior COVID-19
167 infection group and the control group is demonstrated in Fig 2. The log anti-SARS-CoV-2
168 spike-specific antibody titers of the prior COVID-19 infection group were higher than that of the
169 control group in the pre-vaccination, first antibody, and second antibody tests ($p < 0.001$). The log
170 antibody titer of the prior COVID-19 infection group in the first antibody test was significantly
171 higher than that of control group in second antibody test ($p < 0.001$), whereas there was no

172 significant difference of the log antibody titer of the prior COVID-19 infection group between the
173 first antibody test and the second antibody test ($p = 0.54$).

174 The number of adverse reactions after the administration of BNT162b2 vaccine is demonstrated in
175 Table 2. In the prior COVID-19 infection group, the proportion of symptoms was not different
176 between the first and second vaccinations. There was no significant difference of adverse reaction
177 between the first vaccination in the prior COVID-19 infection group and in the second vaccination in
178 control group ($p = 0.84$). The proportion of systemic symptoms of second vaccination in each group
179 was larger than that of the first vaccination in the control group ($p < 0.001$).

180 The proportion of adverse reactions for each day after vaccination is demonstrated in Fig 3. The
181 injection site symptoms and headaches were confirmed in both groups four days after the first and
182 second vaccinations. Fever was confirmed in the early days after the second vaccination in both
183 groups. Fatigue was confirmed after four days of the first and second vaccination doses in the control
184 group, whereas that was confirmed in the early days after both doses in the prior COVID-19
185 infection group. Myalgia and arthralgia were confirmed after four days of the first and second
186 vaccination in the control group, whereas they were confirmed only within three days after receiving
187 the second dose of the vaccination in the prior COVID-19 infection group.

188 The total days of adverse reactions is recorded in Fig 4. The length of the days of systemic symptoms
189 was approximately half the length of the local symptoms, and the mean of days was shorter than 1.5
190 days. The total days of fever and fatigue after the second vaccination was significantly longer than
191 after the first vaccination in both groups ($p < 0.05$, $p < 0.001$). In the control group, the total number
192 of days of myalgia and arthralgia was significantly longer after the second dose of the vaccination
193 than that after the first vaccination ($p < 0.001$), whereas the total number of days of myalgia and
194 arthralgia was longer after the first vaccination than after the second vaccination in the prior
195 COVID-19 infection group.

196 Table 3 shows the multivariate logistic regression analysis of the factors associated with local
197 adverse reactions or systemic adverse reactions after receiving the first vaccination. There were no
198 factors affecting local adverse reactions, whereas females and younger participants experienced
199 significantly enhanced systemic adverse reactions ($p < 0.001$, $p < 0.01$). The history of prior
200 COVID-19 infections was not related to local and systemic adverse reactions ($p = 0.15$, $p = 0.38$).

201

202 **Discussion**

203 In our study, the antibody titer dramatically increased in the prior COVID-19 infection group after
204 first vaccination among Japanese people. This is the first study that evaluated the antibody response
205 after administration of the BNT162b2 vaccine in the prior COVID-19 infection group in Japan.

206 According to previous studies, the median antibody titers after the first dose of vaccination was
207 significantly higher in participants who had been previously infected with the COVID-19 virus than
208 that in uninfected participants [5, 6]. A study carried out by Ebinger et al. shows that the antibody
209 titer reached a plateau after the first dose of the vaccination and that there was no significant
210 difference of antibody titers after the first dose of the vaccination and after the second dose of the
211 vaccination [6]. In our study, the antibody titer of the prior COVID-19 infection group reached a
212 plateau after receiving first dose of the vaccination, and it was significantly higher than that of the
213 control group after receiving the second dose of the vaccination as demonstrated in previous studies.
214 In contrast to the results of previous studies, in our study, the antibody titer of the prior COVID-19
215 infection group after receiving the first dose of the vaccination was significantly higher than that of
216 the control group after receiving the second dose of the vaccination.

217 Based on the results of previous studies, age and gender can be considered to be factors that
218 increased the antibody titer. A study carried by Gustafson et al. showed that the immune response to
219 vaccination is controlled by a delicate balance of effector T cells and follicular T cells and aging
220 disturbs this balance. Multiple changes in T cells have been identified as contributing to the
221 age-related defects of post-transcriptional regulation, metabolic function, and T-cell receptor
222 signaling [8]. In this study, there was no significant difference in age between the prior COVID-19
223 infection group and the control group, but the median age was higher in the prior COVID-19
224 infection group, which may have increased the antibody titer.

225 Differences in sex hormones are associated with gender differences in vaccine-induced immunity.
226 For example, testosterone levels and the antibody titer of the influenza vaccine have been shown to
227 be inversely correlated [9–11]. Genetic differences, as well as sex hormone differences, affect
228 vaccine-induced immunity. The X-chromosome expresses ten times more genes than the
229 Y-chromosome, and the differences in gene expression between the X- and Y-chromosomes promote
230 differences in vaccine-induced immunity by gender [12]. In contrast to this widely held belief, in our
231 previous study, gender was not a significant factor in the differences in antibody titers, and it is
232 possible that gender differences did not contribute much to the increases in antibody titers in this
233 study as well [7].

234 The antibody titer level does not necessarily reflect the immune function against the BNT162b2
235 vaccine as a whole. However, our study showed that prior COVID-19 infection may increase the
236 immune response after receiving the first dose of the vaccination, and this fact is especially important
237 for vaccine delivery systems in Japan.

238 There are very few studies that evaluate the adverse reactions of the BNT162b2 vaccine. The
239 proportion of adverse reactions to the first and second doses of the vaccination in the control group

240 was similar to previous studies [4, 13]. Few studies have shown the adverse reactions to receiving the
241 first and second doses of the vaccination with and without prior COVID-19 infection [6, 14, 15], and
242 they have described the number of days and cases after vaccination, but the range of days were two
243 days or fewer, two to seven days, and seven days or more. On the other hand, the number of adverse
244 reactions were recorded on a daily basis up to the seventh day after vaccination in our study. The
245 trend of fever and fatigue in our study was similar to that of the previous study, whereas
246 injection-site symptoms after the first and second vaccinations in both groups, headache in the prior
247 COVID-19 infection group after both doses, and myalgia and arthralgia after the first vaccination in
248 the prior COVID-19 infection group lasted longer than those of previous study [6].
249 There was no significant difference in the proportion of adverse reactions between the second
250 vaccination in the control group and the first vaccination in the prior COVID-19 infection group.
251 This fact may indicate that prior COVID-19 infection enhances the adverse reaction. On the other
252 hand, in multivariate logistical regression analysis, the history of prior COVID-19 infection was not
253 related to local and systemic adverse reactions, which is likely to be influenced by the sample size.
254 Most adverse reactions in the prior COVID-19 infection group increased after the second vaccination
255 as compared to the adverse reactions after receiving the first vaccination. However, myalgia or
256 arthralgia were reduced or had their duration shortened after patients received the second vaccination.
257 In other words, in the prior COVID-19 infection group, there may be symptom specificity not only in
258 the frequency of adverse reactions, but also in their timing and duration.
259 As mentioned above, our study demonstrates the possibility of enhanced adverse reactions after the
260 first vaccination and a further enhanced adverse reaction to the second vaccination. Judging
261 comprehensively based on the results of antibody titers, it should be recognized that in Japan a single
262 administration of the BNT162b2 vaccine may be sufficient for pre-infected individuals. Further
263 large-scale studies are necessary to evaluate the immune response and the adverse reactions in the
264 prior COVID-19 infection group.
265 Our study has several limitations. First, we did not calculate the lymphocyte activity of either group,
266 and we could not monitor the whole immune system response. Second, although we established a
267 relatively large effect size and although the difference in antibody titer between the two groups was
268 clear, we may have needed a large sample size to assess adverse reactions. Third, we only included
269 relatively healthy medical workers, not participants with severe complications, and this may have
270 reduced the differences between the prior COVID-19 infection group and the control group.
271 In conclusion, our study showed that the antibody response to the first vaccination in the prior
272 COVID-19 infection group was found to be comparable to that of the second vaccination in the

273 non-COVID-19 infection group. On the other hand, the evaluation of adverse reactions is inadequate,
274 and further large-scale studies are needed.

275

276 **Declaration of competing interest:** All authors have no conflicts of interest to declare.

277 **Source of Funding:** none.

278 **IRB Approval Code and Name of the Institution:** Approval No. 2020-Ack-19 / Committee of
279 Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital.

280 **Acknowledgements:** none.

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307 **References:**

- 308 [1] World Health Organization. 2021. WHO Coronavirus (COVID-19) Dashboard. Available from:
309 <https://covid19.who.int>
- 310 [2] The Ministry of Health, Labour and Welfare, Japan. Coronavirus disease 2019 (COVID-19)
311 situation within and outside the country. Available from:
312 http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/newpage_00032.html
- 313 [3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy
314 of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; 383: 2603-2615.
- 315 [4] Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A et al. Safety and
316 Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidate. *N Engl J Med* 2020; 383:
317 2439-50.
- 318 [5] Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T et al. Antibody response
319 to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *Lancet*
320 2021;397(10279):1057-1058.
- 321 [6] Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC et al. Antibody responses to the
322 BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med*
323 2021;27(6):981-984.
- 324 [7] Mitsunaga T, Ohtaki Y, Seki Y, Yoshioka M, Mori H, Suzuka M et al. The evaluation of factors
325 affecting antibody response after administration of the BNT162b2 vaccine: A prospective study
326 in Japan. *medRxiv* 2021. Doi: <https://doi.org/10.1101/2021.06.20.21259177>.
- 327 [8] Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine
328 responses. *J Allergy Clin Immunol* 2020; 145(5): 1309-1321.
- 329 [9] Markle JG, Fish EN. Sex matters in immunity. *Trends Immunol* 2014; 35: 97-104.
- 330 [10] Ruggieri A, Anticoli S, D' Ambrosio A, Giordani L, Viora M. The influence of sex and gender
331 on immunity, infection and vaccination. *Ann Ist Super Sanita* 2016; 52: 198-204.
- 332 [11] Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiébaud R et al. Systems analysis of
333 sex differences reveals an immunosuppressive role for testosterone in the response to influenza
334 vaccination. *Proc Natl Acad Sci USA* 2014; 111(2): 869-874.
- 335 [12] Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced
336 humoral immunity. *Seminars in immunopathology* 2019; 41: 239-249.
- 337 [13] Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S et al. Adverse Reactions of the Second
338 Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea. *J Korean*
339 *Med Sci* 2021; 36(21): e153.

340 [14] Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P et al. Vaccine side-effects and
341 SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK:
342 a prospective observational study. *Lancet Infect Dis* 2021; 21:939-49.

343 [15] Raw RK, Kelly C, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection but not
344 Long-COVID is associated with increased adverse events following BNT162b2/Pfizer
345 vaccination. *medRxiv* 2021. Doi: <https://doi.org/10.1101/2021.04.15.21252192>.

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371 Fig.1. Flow chart of participant's selection with inclusion and exclusion data

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388


389

390

391

392

393



394 Table 1. Baseline characteristics of the study population.

	Prior COVID-19 infection Group (n=9) Median (interquartile range)	Control Group (n=374) Median (interquartile range)	p-value
Age, years	26 (16.0)	36 (16.0)	0.12
Sex [n (%)]			0.46
Male	1 (11.1)	110 (29.4)	
Female	8 (88.9)	264 (70.6)	
Body Mass Index (BMI), kg/m ²			0.82
BMI < 18.5	0 (0)	34 (9.1)	
18.5 ≤ BMI <25	7 (77.8)	268 (71.7)	
25 ≤ BMI <30	2 (22.2)	53 (14.2)	
30 ≤ BMI <35	0 (0)	14 (3.7)	
35 ≤ BMI <40	0 (0)	5 (1.3)	
Past Medical Histories [n (%)]			0.56
Chronic lung disease (COPD)	0 (0)	1 (0.3)	
Chronic lung disease (non-COPD)	1 (11.1)	34 (9.1)	
Cardiac disease	0 (0)	6 (1.6)	
Hypertension	0 (0)	30 (8.0)	
Diabetes	0 (0)	6 (1.6)	
Dyslipidemia	0 (0)	16 (4.3)	
Liver disease	0 (0)	6 (1.6)	
Chronic kidney disease	0 (0)	4 (1.1)	
Autoimmune disease	0 (0)	7 (1.9)	
Cancer	1 (11.1)	8 (2.1)	
Medication [n (%)]			1.00
Antihypertensive drug	0 (0)	28 (7.5)	
Antidiabetic drug	0 (0)	5 (1.3)	
Antilipid drug	0 (0)	13 (3.5)	
Anticoagulant / Antiplatelet drug	0 (0)	2 (0.5)	
Immunosuppressive drug	0 (0)	3 (0.8)	
Immunoglobulin	0 (0)	4 (1.1)	
Current smoking [n (%)]	1 (11.1)	70 (18.7)	1.00

Past smoking [n (%)]		3 (33.3)	64 (17.1)	0.20
Drinking Alcohol [n (%)]		6 (66.7)	229 (61.2)	1.00
Laboratory test				
WBC	[$\times 10^3/\mu\text{L}$]	6.8 (1.5)	6.35 (2.0)	0.71
Hb	[g/dL]	13.4 (0.1)	13.9 (1.7)	0.16
Ht	[%]	39.2 (1.9)	40.2 (4.5)	0.20
PLT	[$\times 10^4/\mu\text{L}$]	26.8 (4.9)	25.2 (7.3)	0.90
Alb	[g/dL]	4.6 (0.2)	4.6 (0.4)	0.37
AST	[U/L]	18.0 (5.0)	19.0 (6.0)	0.94
ALT	[U/L]	15.0 (5.0)	15.0 (12.0)	0.80
γ -GT	[U/L]	16.0 (13.0)	17.0 (12.8)	0.76
Cr	[mg/dL]	0.7 (0.1)	0.6 (0.2)	0.57
CRP	[mg/dL]	0.03 (0.06)	0.03 (0.05)	0.71
BS	[mg/dL]	93 (13.0)	90 (13.0)	0.71
HbA1c	[%]	5.5 (0.3)	5.5 (0.4)	0.97
HDL-C	[mg/dL]	59.0 (16.0)	65.0 (19.0)	0.21
LDL-C	[mg/dL]	115 (29.0)	107 (35.0)	0.60
TG	[mg/dL]	72.0 (42.0)	74.0 (59.0)	0.57
The length of days for vaccination and antibody test, days				
1st vaccination to 1st antibody test		8.0 (1.0)	8.0 (1.0)	0.68
2nd vaccination to 2nd antibody test		8.0 (1.0)	8.0 (1.0)	0.63
1st vaccination to 2nd vaccination		24.5 (3.0)	22.0 (3.0)	0.40

395 Data are presented as the median (interquartile range) for continuous variables and the number (%)

396 for categorical variables.

397 COPD, Chronic obstructive pulmonary disease; WBC, White blood cells; Hb, Hemoglobin; Ht,

398 Hematocrit; PLT, Platelets; Alb, Albumin; AST, Aspartate aminotransferase; ALT, alanine

399 aminotransferase; γ -GT, γ -glutamyl transpeptidase; Cr, Creatinine; CRP, C-reactive protein; BS,

400 Blood sugar; HbA1c, Hemoglobin A1c; HDL-C, High density lipoprotein cholesterol; LDL-C, Low

401 density lipoprotein cholesterol; TG, Triglyceride.

402


403

404

405

406

407 Fig. 2. Anti-SARS-CoV-2 spike-specific antibody response after the administration of the BNT162b2 vaccine to participants with and without
408 prior COVID-19 infection.




430 Table 2. The number of adverse reactions after the administration of the BNT162b2 vaccine between the two groups.

	Prior COVID-19 infection Group (n=7)		Control Group (n=359)		p-value					
	First vaccination (pFV)	Second vaccination (pSV)	First vaccination (cFV)	Second vaccination (cSV)	pFV vs pSV	pFV vs cFV	pFV vs cSV	pSV vs cFV	pSV vs cSV	cFV vs cSV
The number of the cases (%)										
Injection site symptoms	6 (85.7)	6 (85.7)	352 (98.1)	351 (97.8)	0.64	0.24	0.84	$p < 0.001$	0.91	$p < 0.001$
fever	1 (14.3)	5 (71.4)	5 (1.4)	161 (44.8)						
fatigue	2 (28.6)	4 (57.1)	99 (27.6)	249 (69.4)						
headache	2 (28.6)	3 (42.9)	77 (21.4)	215 (59.9)						
chills	0 (0)	3 (42.9)	23 (6.4)	141 (39.3)						
diarrhea	0 (0)	0 (0)	27 (7.5)	50 (13.9)						
myalgia	3 (42.9)	2 (28.6)	106 (29.5)	166 (46.2)						
arthralgia	2 (28.6)	3 (42.9)	27 (7.5)	160 (44.6)						
others	0 (0)	0 (0)	38 (10.6)	71 (19.8)						

431
432
433
434
435
436
437
438
439

440 Fig. 3. The proportion of adverse reactions for each day after the administration of the BNT162b2
 441 vaccine.



474 Fig. 4. The total days of adverse reactions after the administration of the BNT162b2 vaccine.

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491


492

493

494

495

496



497 Table 3. The multivariate logistic regression analysis of the factors associated with local and systemic adverse reactions after receiving the first
 498 vaccination.

Symptoms/Predictor	Adjusted OR (95% CI)	<i>p</i> -value
Local reactions		
Female	0.47 (0.05 – 4.19)	0.50
Age	1.04 (0.97 – 1.14)	0.26
Body Mass Index: BMI	1.03 (0.83 – 1.29)	0.77
Prior Covid-19 infection	0.18 (0.02 – 1.82)	0.15
Systemic reactions		
Female	4.12 (2.45 – 6.90)	<i>p</i> < 0.001
Age	0.97 (0.95 – 0.99)	<i>p</i> < 0.01
Body Mass Index: BMI	1.05 (0.99 – 1.12)	0.13
Prior Covid-19 infection	0.50 (0.11 – 2.36)	0.38

499

500

501